Exact Sciences Co. (NASDAQ:EXAS) Shares Bought by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. grew its position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 35.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 95,827 shares of the medical research company's stock after acquiring an additional 24,992 shares during the period. Harbor Capital Advisors Inc. owned about 0.05% of Exact Sciences worth $5,385,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Diversified Trust Co increased its holdings in shares of Exact Sciences by 5.9% in the 4th quarter. Diversified Trust Co now owns 12,639 shares of the medical research company's stock valued at $710,000 after purchasing an additional 708 shares in the last quarter. Everence Capital Management Inc. purchased a new position in Exact Sciences in the fourth quarter valued at about $356,000. Modus Advisors LLC acquired a new stake in shares of Exact Sciences during the 4th quarter valued at approximately $43,000. GAMMA Investing LLC boosted its stake in shares of Exact Sciences by 29.1% during the 4th quarter. GAMMA Investing LLC now owns 3,674 shares of the medical research company's stock worth $206,000 after acquiring an additional 828 shares in the last quarter. Finally, American Trust acquired a new stake in shares of Exact Sciences in the 3rd quarter worth approximately $229,000. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

EXAS has been the topic of several recent research reports. Stifel Nicolaus decreased their price objective on shares of Exact Sciences from $82.00 to $67.00 and set a "buy" rating on the stock in a research report on Wednesday, November 6th. Benchmark lowered their price target on shares of Exact Sciences from $67.00 to $65.00 and set a "buy" rating on the stock in a research report on Wednesday, November 6th. Canaccord Genuity Group cut their price objective on Exact Sciences from $95.00 to $75.00 and set a "buy" rating for the company in a research report on Wednesday, November 6th. Bank of America lowered their target price on Exact Sciences from $75.00 to $72.00 and set a "buy" rating on the stock in a report on Friday, December 13th. Finally, The Goldman Sachs Group cut their price target on Exact Sciences from $75.00 to $65.00 and set a "buy" rating for the company in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $72.94.

Exact Sciences Trading Down 0.3 %

Shares of EXAS stock traded down $0.18 on Friday, reaching $56.50. 2,458,044 shares of the stock were exchanged, compared to its average volume of 1,943,391. Exact Sciences Co. has a 1-year low of $40.62 and a 1-year high of $79.62. The stock has a market cap of $10.46 billion, a P/E ratio of -48.29 and a beta of 1.24. The company has a quick ratio of 1.93, a current ratio of 2.12 and a debt-to-equity ratio of 0.72. The firm has a 50 day moving average of $57.82 and a two-hundred day moving average of $58.78.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.01). The firm had revenue of $708.66 million during the quarter, compared to analysts' expectations of $716.80 million. Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. The business's revenue for the quarter was up 12.8% on a year-over-year basis. On average, research analysts anticipate that Exact Sciences Co. will post -1.13 EPS for the current year.

Insider Transactions at Exact Sciences

In related news, CEO Kevin T. Conroy purchased 19,500 shares of the firm's stock in a transaction on Wednesday, November 13th. The stock was purchased at an average price of $51.35 per share, for a total transaction of $1,001,325.00. Following the acquisition, the chief executive officer now directly owns 1,074,191 shares in the company, valued at $55,159,707.85. The trade was a 1.85 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.36% of the company's stock.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.